Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kelch domain-containing protein 3 (KLHDC3) is a substrate-specific adaptor for Cullin-RING E3 ligase complexes, particularly the CRL2(KLHDC3). It recognizes protein substrates with a C-terminal glycine and mediates their ubiquitination and subsequent degradation[5]. KLHDC3 belongs to a family of proteins characterized by the Kelch domain, a β-propeller structure known for protein–protein interaction and substrate recognition[2][3]. Unlike many Kelch proteins, KLHDC3 lacks BTB and BACK domains, distinguishing it structurally within the family. Originally identified for its role in targeting defective selenoproteins, KLHDC3 forms part of the cellular machinery maintaining protein homeostasis, specifically recognizing specific C-terminal degron motifs such as -RG, -KG, or -QG, facilitating turnover of aberrant proteins[3][5]. There is currently no published direct association with drug interactions or pathological biomarkers, but its functional category is crucial for cell biology and potentially relevant to disease if dysregulated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Kelch domain-containing protein 3 (KLHDC3).